Young adults with ALL have encouraging survival with pediatric regimen
12/08/2015
Using a pediatric chemotherapy regimen to treat young adults with acute lymphoblastic leukemia (ALL) significantly improved their outcomes compared to what has historically been achieved with 'adult...
Experimental drug is first targeted therapy to improve survival in high-risk AML patients
12/08/2015
Midostaurin added to standard chemotherapy is the first targeted treatment to improve survival of a high-risk, genetically defined subgroup of patients with acute myeloid leukemia (AML), reported Dr.
Julian Steinwachs and colleagues at the Biophysics Group investigated tumour cell migration in artificial connective tissue made of collagen, which mimics the natural matrix of organs in terms of its...
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders...
Tiny drug-laden 'popping bubbles' lead triple attack treatment for liver cancer
12/08/2015
In an interdisciplinary collaboration between prominent academic and industry investigators, researchers have discovered a novel method for repositioning an FDA-approved anti-cancer compound so it...
Researchers reveal the nature of atherosclerosis from plaque initiation to thrombosis
12/08/2015
For the first time, researchers can provide early detection of plaques that have a high likelihood of clotting and/or rupture.
New data finds benefit of rivaroxaban treatment in patients with blood clots and cancer
12/08/2015
Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, have announced the first results from CALLISTO, a comprehensive research program that includes nine studies of their...
Leukemia patients who switched kinase inhibitors had favorable outcomes
12/08/2015
Chronic lymphocytic leukemia (CLL) patients who stopped taking the kinase inhibitors (KIs), ibrutinib or idelalisib, had mostly favorable outcomes when they switched to the alternate therapy...
Drug shows potential as safe and effective for most prevalent form of adult leukemia
12/08/2015
Phase I/II clinical trial data shows up to 95 percent response rate in relapsed chronic lymphocytic leukemia.
1st tool to assess impact of co-illnesses in young cancer patients
12/08/2015
A team of researchers from LSU Health New Orleans Schools of Public Health and Medicine and colleagues have developed the first index identifying and documenting concurrent but unrelated diseases...